Rick Bienkowski
Stock Analyst at Cantor Fitzgerald
(0.22)
# 4,074
Out of 4,818 analysts
37
Total ratings
12.9%
Success rate
-32.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERV Verve Therapeutics | Upgrades: Overweight | n/a | $5.78 | - | 4 | Apr 15, 2025 | |
| BEAM Beam Therapeutics | Reiterates: Overweight | n/a | $20.17 | - | 12 | Mar 12, 2025 | |
| LEGN Legend Biotech | Reiterates: Overweight | $83 | $34.24 | +142.41% | 2 | Dec 9, 2024 | |
| ACLX Arcellx | Initiates: Overweight | n/a | $63.97 | - | 1 | Sep 3, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Overweight | $65 | $8.18 | +694.62% | 7 | Jun 24, 2024 | |
| CRBU Caribou Biosciences | Initiates: Neutral | n/a | $0.85 | - | 1 | Nov 8, 2023 | |
| EDIT Editas Medicine | Reiterates: Overweight | $14 | $1.61 | +769.57% | 6 | Sep 13, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $112 → $107 | $39.08 | +173.80% | 4 | Aug 8, 2022 |
Verve Therapeutics
Apr 15, 2025
Upgrades: Overweight
Price Target: n/a
Current: $5.78
Upside: -
Beam Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $20.17
Upside: -
Legend Biotech
Dec 9, 2024
Reiterates: Overweight
Price Target: $83
Current: $34.24
Upside: +142.41%
Arcellx
Sep 3, 2024
Initiates: Overweight
Price Target: n/a
Current: $63.97
Upside: -
Intellia Therapeutics
Jun 24, 2024
Reiterates: Overweight
Price Target: $65
Current: $8.18
Upside: +694.62%
Caribou Biosciences
Nov 8, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.85
Upside: -
Editas Medicine
Sep 13, 2023
Reiterates: Overweight
Price Target: $14
Current: $1.61
Upside: +769.57%
CRISPR Therapeutics AG
Aug 8, 2022
Maintains: Outperform
Price Target: $112 → $107
Current: $39.08
Upside: +173.80%